Microphysiological Tissue Models of Metabolic Disease

The overarching aim of the Microphysiological Tissue Models group is to to narrow the translational gap between preclinical research and clinical programs in order to reduce drug development times, increase R&D success rates and improve patient health. To this end, we bioengineer human model systems that closely recapitulate human tissue phenotypes and functions. By integrating primary patient-derived tissues, advanced bioprinting, microfluidics and chemogenomics, we aim to create predictive, adaptive and mechanistically transparent platforms for pharmacological and toxicological research that accelerate discovery and improve translational fidelity with an emphasis on clinically actionable insights to directly address unmet needs for the treatment of metabolic disease and cancer.